
Suffering from Moderate to Severe Hidradenitis Suppurativa?
Trial – Acrotech Incyte is conducting a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXXXXXX in Participants with Moderate to Severe Hidradenitis
Trial – Acrotech Incyte is conducting a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXXXXXX in Participants with Moderate to Severe Hidradenitis
Trial – Acrotech Acrotech is conducting an Open-label Study to Assess the Long-Term Safety of XXXXXXXX Ointment in Mild to Moderate Atopic Dermatitis. To participate
Trial – Eli Lilly Eli Lilly is conducting a US-Based Observational Study of Nail and Scalp Psoriasis Improvement in Patients Treated with Ixekizumab (Taltz) To participate
Trial – Eli Lilly Eli Lilly is conducting an Open-Label Study of XXXXXXXXXX in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of
Trial – Eli Lilly Eli Lilly is conducting an Open-Label Study of XXXXXXXXXX in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With
Trial – Syneos Health/Eli Lilly Eli Lilly and Company are conducting a Long-term Study to Assess the Safety and Efficacy of xxxxxxxxxxx in Patients With Moderate-to-Severe
Trial -Novartis A multicenter, double-blind, randomized withdrawal extension study of subcutaneous XXXXXXXXXX to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe
Trial -DermTech A Multi-center Sample Collection Study in Patients with a variety of skin conditions including but not limited to Melanoma, Squamous Cell Carcinoma, and
Trial -ICON/Trevi This 1 year study aims to determine the evaluate the safety, tolerability, and effectiveness of nalbuphine as a treatment for the itching related
Lorem ipsum dolor sit amet, consectetur adiop iscing elit, sed do eiusmod tempor inci didunt ult labore et dolore magna aliqua.